These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

424 related items for PubMed ID: 24673708

  • 1. Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results.
    Jackson GH, Morgan GJ, Davies FE, Wu P, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross FM, Byrne J, Roddie H, Rudin C, Boyd KD, Osborne WL, Cook G, Child JA.
    Br J Haematol; 2014 Jul; 166(1):109-17. PubMed ID: 24673708
    [Abstract] [Full Text] [Related]

  • 2. Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial.
    Morgan GJ, Davies FE, Gregory WM, Szubert AJ, Bell SE, Drayson MT, Owen RG, Ashcroft AJ, Jackson GH, Child JA, National Cancer Research Institute Haematological Oncology Clinical Studies Group.
    Blood; 2012 Jun 07; 119(23):5374-83. PubMed ID: 22498739
    [Abstract] [Full Text] [Related]

  • 3. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.
    Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross F, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Child JA, National Cancer Research Institute Haematological Oncology Clinical Study Group.
    Lancet; 2010 Dec 11; 376(9757):1989-99. PubMed ID: 21131037
    [Abstract] [Full Text] [Related]

  • 4. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial.
    Morgan GJ, Child JA, Gregory WM, Szubert AJ, Cocks K, Bell SE, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross FM, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Wu P, Davies FE, National Cancer Research Institute Haematological Oncology Clinical Studies Group.
    Lancet Oncol; 2011 Aug 11; 12(8):743-52. PubMed ID: 21771568
    [Abstract] [Full Text] [Related]

  • 5. Prospective observational study of treatment pattern, effectiveness and safety of zoledronic acid therapy beyond 24 months in patients with multiple myeloma or bone metastases from solid tumors.
    Van den Wyngaert T, Delforge M, Doyen C, Duck L, Wouters K, Delabaye I, Wouters C, Wildiers H.
    Support Care Cancer; 2013 Dec 11; 21(12):3483-90. PubMed ID: 23955094
    [Abstract] [Full Text] [Related]

  • 6. The Medical Research Council Myeloma IX trial: the impact on treatment paradigms.
    Richardson PG, Laubach JP, Schlossman RL, Ghobrial IM, Mitsiades CS, Rosenblatt J, Mahindra A, Raje N, Munshi N, Anderson KC.
    Eur J Haematol; 2012 Jan 11; 88(1):1-7. PubMed ID: 21991938
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of zoledronic acid vs clodronic acid for newly-diagnosed multiple myeloma from the United Kingdom healthcare system perspective.
    Delea TE, Rotter J, Taylor M, Chandiwana D, Bains M, El Ouagari K, Kaura S, Morgan GJ.
    J Med Econ; 2012 Jan 11; 15(3):454-64. PubMed ID: 22316275
    [Abstract] [Full Text] [Related]

  • 8. Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid.
    Cetiner S, Sucak GT, Kahraman SA, Aki SZ, Kocakahyaoglu B, Gultekin SE, Cetiner M, Haznedar R.
    J Bone Miner Metab; 2009 Jan 11; 27(4):435-43. PubMed ID: 19240969
    [Abstract] [Full Text] [Related]

  • 9. Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study.
    Raje N, Vescio R, Montgomery CW, Badros A, Munshi N, Orlowski R, Hadala JT, Warsi G, Argonza-Aviles E, Ericson SG, Anderson KC.
    Clin Cancer Res; 2016 Mar 15; 22(6):1378-84. PubMed ID: 26644410
    [Abstract] [Full Text] [Related]

  • 10. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: definition and management of the risk related to zoledronic acid.
    Cafro AM, Barbarano L, Nosari AM, D'Avanzo G, Nichelatti M, Bibas M, Gaglioti D, Taroni A, Riva F, Morra E, Andriani A.
    Clin Lymphoma Myeloma; 2008 Apr 15; 8(2):111-6. PubMed ID: 18501105
    [Abstract] [Full Text] [Related]

  • 11. The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program.
    Grbic JT, Black DM, Lyles KW, Reid DM, Orwoll E, McClung M, Bucci-Rechtweg C, Su G.
    J Am Dent Assoc; 2010 Nov 15; 141(11):1365-70. PubMed ID: 21037195
    [Abstract] [Full Text] [Related]

  • 12. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.
    Terpos E, Morgan G, Dimopoulos MA, Drake MT, Lentzsch S, Raje N, Sezer O, García-Sanz R, Shimizu K, Turesson I, Reiman T, Jurczyszyn A, Merlini G, Spencer A, Leleu X, Cavo M, Munshi N, Rajkumar SV, Durie BG, Roodman GD.
    J Clin Oncol; 2013 Jun 20; 31(18):2347-57. PubMed ID: 23690408
    [Abstract] [Full Text] [Related]

  • 13. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer.
    Coleman R, Woodward E, Brown J, Cameron D, Bell R, Dodwell D, Keane M, Gil M, Davies C, Burkinshaw R, Houston SJ, Grieve RJ, Barrett-Lee PJ, Thorpe H.
    Breast Cancer Res Treat; 2011 Jun 20; 127(2):429-38. PubMed ID: 21394500
    [Abstract] [Full Text] [Related]

  • 14. Bisphosphonates in multiple myeloma: an updated network meta-analysis.
    Mhaskar R, Kumar A, Miladinovic B, Djulbegovic B.
    Cochrane Database Syst Rev; 2017 Dec 18; 12(12):CD003188. PubMed ID: 29253322
    [Abstract] [Full Text] [Related]

  • 15. Altered microRNA expression profile in the peripheral lymphoid compartment of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw.
    Musolino C, Oteri G, Allegra A, Mania M, D'Ascola A, Avenoso A, Innao V, Allegra AG, Campo S.
    Ann Hematol; 2018 Jul 18; 97(7):1259-1269. PubMed ID: 29546453
    [Abstract] [Full Text] [Related]

  • 16. Safety of I.V. Nonnitrogen bisphosphonates on the occurrence of osteonecrosis of the jaw: long-term follow-up on prostate cancer patients.
    Rodrigues P, Hering F, Imperio M.
    Clin Genitourin Cancer; 2015 Jun 18; 13(3):199-203. PubMed ID: 25475039
    [Abstract] [Full Text] [Related]

  • 17. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
    Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA.
    J Clin Oncol; 2005 Dec 01; 23(34):8580-7. PubMed ID: 16314620
    [Abstract] [Full Text] [Related]

  • 18. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.
    Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, Diel IJ, Takahashi S, Shore N, Henry DH, Barrios CH, Facon T, Senecal F, Fizazi K, Zhou L, Daniels A, Carrière P, Dansey R.
    Ann Oncol; 2012 May 01; 23(5):1341-1347. PubMed ID: 21986094
    [Abstract] [Full Text] [Related]

  • 19. Osteonecrosis of the Jaw After Bisphosphonates Treatment in Patients with Multiple Myeloma.
    Krstevska S, Stavric SG, Cevrevska L, Georgjievski B, Karanfilski O, Sotirova T, Balkanov T.
    Med Arch; 2015 Dec 01; 69(6):367-70. PubMed ID: 26843726
    [Abstract] [Full Text] [Related]

  • 20. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid.
    Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, Migkou M, Eleftherakis-Papaiakovou E, Christoulas D, Terpos E, Bamias A.
    Ann Oncol; 2009 Jan 01; 20(1):117-20. PubMed ID: 18689864
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.